COCH · Envoy Medical Inc. Class A Common Stock
View on chartInsiders & Stakes
| Glen A. Taylor 10% Owner | ▲ Buy | Open Market | 21,703,607 Shares held | 2/12/2026 | View profile |
| Charles Brynelsen Director | ▲ Buy | Open Market | 1,050,000 Shares held | 2/12/2026 | View profile |
| Mona Chetan Patel Director | ▲ Buy | Open Market | 332,500 Shares held | 2/12/2026 | View profile |
| Brent T. Lucas Chief Executive Officer | ▲ Buy | Grant | 329,946 Shares held | 5/29/2026 | View profile |
| Robert Potashnick Interim CFO | ▲ Buy | Open Market | 212,500 Shares held | 2/12/2026 | View profile |
| Susan Kantor Director | ▲ Buy | Open Market | 174,037 Shares held | 2/12/2026 | View profile |
| Priya Cherian Huskins Director | ▼ Sell | Other | 25,000 Shares held | 9/29/2023 | View profile |
| Diane L. Dewbrey Director | ▼ Sell | Other | 25,000 Shares held | 9/29/2023 | View profile |
| Hirsch Daniel J. Director | ▼ Sell | Other | 25,000 Shares held | 9/29/2023 | View profile |
| Anzu SPAC GP I LLC 10% Owner | ▼ Sell | Other | 0 Shares held | 12/23/2024 | View profile |
Transaction History
| Brent T. Lucas | ▲ Buy | Grant | 32,856 | $20K | 5/29/2026 |
| Susan Kantor | ▲ Buy | Open Market | 96,150 | $38K | 2/12/2026 |
| Charles Brynelsen | ▲ Buy | Open Market | 1,000,000 | $400K | 2/12/2026 |
| Robert Potashnick | ▲ Buy | Open Market | 212,500 | $85K | 2/12/2026 |
| Mona Chetan Patel | ▲ Buy | Open Market | 312,500 | $125K | 2/12/2026 |
| Brent T. Lucas | ▲ Buy | Open Market | 62,500 | $25K | 2/12/2026 |
| Glen A. Taylor | ▲ Buy | Open Market | 18,750,000 | $7.5M | 2/12/2026 |
| Brent T. Lucas | ▲ Buy | Grant | 18,105 | $13K | 11/28/2025 |
| Mona Chetan Patel | ▲ Buy | Open Market | 2,500 | $4K | 6/11/2025 |
| Mona Chetan Patel | ▲ Buy | Open Market | 10,000 | $15K | 6/6/2025 |
| Brent T. Lucas | ▲ Buy | Grant | 7,742 | $10K | 5/30/2025 |
| Charles Brynelsen | ▲ Buy | Open Market | 35,000 | $58K | 5/27/2025 |
| Charles Brynelsen | ▲ Buy | Open Market | 13,000 | $21K | 5/23/2025 |
| Charles Brynelsen | ▲ Buy | Open Market | 2,000 | $3K | 5/22/2025 |
| Susan Kantor | ▼ Sell | Other | 34,705 | $0 | 12/23/2024 |
| Anzu SPAC GP I LLC | ▼ Sell | Other | 2,028,986 | $0 | 12/23/2024 |
| Anzu SPAC GP I LLC | ▼ Sell | Other | 1,028,986 | $0 | 12/20/2024 |
| Brent T. Lucas | ▲ Buy | Grant | 5,165 | $10K | 11/30/2024 |
| Mona Chetan Patel | ▲ Buy | Open Market | 2,500 | $6K | 11/20/2024 |
| Susan Kantor | ▼ Sell | Other | 18,182 | $0 | 11/19/2024 |
| Anzu SPAC GP I LLC | ▼ Sell | Other | 1,000,000 | $0 | 11/19/2024 |
| Mona Chetan Patel | ▲ Buy | Open Market | 4,000 | $13K | 9/11/2024 |
| Mona Chetan Patel | ▲ Buy | Open Market | 1,000 | $3K | 9/9/2024 |
| Brent T. Lucas | ▼ Sell | Other | 74,784 | $0 | 6/24/2024 |
| Brent T. Lucas | ▼ Sell | Other | 10,176 | $0 | 6/24/2024 |
| Brent T. Lucas | ▲ Buy | Open Market | 10,000 | $10K | 11/21/2023 |
| Brent T. Lucas | ▲ Buy | Open Market | 2,380 | $2K | 11/21/2023 |
| Anzu SPAC GP I LLC | ▼ Sell | Other | 2,490,000 | — | 9/29/2023 |
| Anzu SPAC GP I LLC | ▼ Sell | Other | 490,000 | — | 9/29/2023 |
| Priya Cherian Huskins | ▼ Sell | Other | 25,000 | $0 | 9/29/2023 |
| Susan Kantor | ▼ Sell | Other | 25,000 | — | 9/29/2023 |
| Hirsch Daniel J. | ▼ Sell | Other | 25,000 | $0 | 9/29/2023 |
| Diane L. Dewbrey | ▼ Sell | Other | 25,000 | $0 | 9/29/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Envoy Medical Adds Two New Patents to Global Portfolio
Envoy Medical announced it has been granted two additional global patents, further expanding its intellectual property portfolio. This development strengthens the company's protection for its medical technologies. The stock is currently trading near its 52-week low, with an average analyst target of $2.00.
Envoy Medical Adds Two New Patents to Global Portfolio. Envoy Medical announced it has been granted two additional global patents, further expanding its intellectual property portfolio. This development strengthens the company's protection for its medical technologies. The stock is currently trading near its 52-week low, with an average analyst target of $2.00.